{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_21320", "batch_size": 200, "batch_pos": 64, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment uses neutral/procedural language without high-potency verbs or metaphors.", "method": "llm_batch", "batch_id": "batch_2_6436", "batch_size": 200, "batch_pos": 54, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb from the specified list paired with scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_2444", "batch_size": 200, "batch_pos": 21, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
